“Coordination between urology and radiation oncology, if urology is placing the device, is really critical,” says Jonathan E. Shoag, MD.
In this video, Jonathan E. Shoag, MD, and Daniel E. Spratt, MD, also discuss how the UH Seideman Cancer Center radiation oncology practice for prostate cancer has grown. Shoag is a urologist at University Hospitals and an assistant professor of urology at Case Western Reserve University School of Medicine, and Spratt is chair of Radiation Oncology at UH Cleveland Medical Center and a professor at Case Western Reserve University School of Medicine.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
2 Commerce Drive
Cranbury, NJ 08512